Research Summary

I'm a physician-scientist who sees prostate cancer patients, and runs a prostate cancer-focused research lab. Our focus is in understanding hormone-related tumor evolution and dynamics. Understanding how tumors shift their dependencies and identity during therapy is critical to improving patients' clinical care.

Research Funding

  • September 15, 2023 - August 31, 2028 - Simulating Ancestrally Unbiased Tumor Evolution to Interrogate Drug Resistance , Principal Investigator . Sponsor: NIH Common Fund, Sponsor Award ID: DP2CA290244
  • July 1, 2022 - June 30, 2026 - Interrogating tumor sub-clonality and shifting dependencies to reduce castration therapy , . Sponsor: American Cancer Society, Sponsor Award ID: RSG-22-021-01-CDP
  • June 20, 2023 - June 19, 2026 - Profiling and Eliminating Tumor Subclones Destined for Resistance , . Sponsor: DOD Prostate Cancer Program, Sponsor Award ID: P0563731
  • September 15, 2018 - August 31, 2023 - Investigating How a Balance of Negative and Positive ETS Factors Controls Prostate Oncogenesis , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08CA226348

Education

University of Saskatchewan, BSc Dble Honors, 04/1999, Biochemistry, Microbiology & Immunology
University of Toronto, MD, 06/2008, Medicine
University of Toronto, PhD, 11/2008, Molecular Genetics, Jeff Wrana’s Lab
Weill Cornell Medicine, Resident, 06/2010, Internal Medicine, Medical Research Track
Memorial Sloan Kettering, Clinical Fellow, 06/2016, Medical Oncology, Medical Research Track
Memorial Sloan Kettering, Postdoctoral Fellow, 05/2018, Human Oncology, Charles Sawyers’ Lab

Honors & Awards

  • 1999
    Earl of Bessborough Prize for Most Distinguished Graduate Receiving a B.Sc., U of Sask
  • 1999
    Haslam Medal for Most Distinguished Graduate of College of Arts and Sciences, U of Sask
  • 1999
    JF Morgan Memorial Award for Highest Academic Achievement, Microbiology B.Sc., U of Sask
  • 1999
    Merit in Biochemistry Award, Society of Chemical Industry
  • 2004
    Young Investigator Award for Distinguished Project, Canadian Society for Clinical InvestigationScholarship for Cancer Research Conference, ISREC
  • 2005
    George Brown Medical Student Research Day Award, University of Toronto
  • 2006
    Robert and Francine Ruggles Family Graduate Fellowship, University of Toronto
  • 2007
    Dr. Ruth Kurdyak Memorial Medical Alumni Student Award, University of Toronto
  • 2007
    Ruffo Graduate Fellowship for Outstanding Achievement during MD/PhD, University of Toronto
  • 2008
    Lois & K.J.R. Wightman Award for Interest in Internal Medicine, University of Toronto
  • 2011
    John Mendelsohn Housestaff Teaching Award, Memorial Sloan Kettering Cancer Center
  • 2011-2013
    Dana Fellow in Biomedical Research, Clinical Scholars Training Program
  • 2013-2015
    Postdoctoral Research Training Award, US Dept of Defense, Prostate Cancer Program
  • 2013
    Young Investigator Award, Conquer Cancer Foundation of ASCO
  • 2015 - 2019
    Physician Research Training Award, US Dept of Defense, Prostate Cancer Program
  • 2016
    Merit Award in Genitourinary Cancer, Conquer Cancer Foundation of ASCO
  • 2016 – 2019
    Young Investigator Award, Prostate Cancer Foundation

Selected Publications

  1. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma PatientsTreated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 May 17.  View on PubMed
  2. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089.  View on PubMed
  3. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023 03; 41(3):145.e7-145.e15.  View on PubMed
  4. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 11 02; 82(21):3888-3902.  View on PubMed
  5. Ogura K, Elkrief A, Bowman AS, Koche RP, de Stanchina E, Benayed R, Mauguen A, Mattar MS, Khodos I, Meyers PA, Healey JH, Tap WD, Hameed M, Zehir A, Shukla N, Sawyers C, Bose R, Slotkin E, Ladanyi M. Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance. JCO Precis Oncol. 2022 08; 6:e2200048.  View on PubMed
  6. Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J. Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. JCO Oncol Pract. 2022 05; 18(5):e648-e658.  View on PubMed
  7. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 08; 52(8):778-789.  View on PubMed
  8. Ryan MJ, Bose R. Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. Front Oncol. 2019; 9:1287.  View on PubMed
  9. Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, Leslie CS, Sawyers CL. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019 07; 571(7765):408-412.  View on PubMed
  10. Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y, International SU2C/PCF Prostate Cancer Dream Team, Zheng D, Schultz N, Sawyers CL. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature. 2017 06 29; 546(7660):671-675.  View on PubMed
  11. Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL. A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):14028-33.  View on PubMed
  12. Narimatsu M, Bose R, Pye M, Zhang L, Miller B, Ching P, Sakuma R, Luga V, Roncari L, Attisano L, Wrana JL. Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell. 2009 Apr 17; 137(2):295-307.  View on PubMed
  13. Bose R, Wrana JL. Regulation of Par6 by extracellular signals. Curr Opin Cell Biol. 2006 Apr; 18(2):206-12.  View on PubMed
  14. Wang HR, Ogunjimi AA, Zhang Y, Ozdamar B, Bose R, Wrana JL. Degradation of RhoA by Smurf1 ubiquitin ligase. Methods Enzymol. 2006; 406:437-47.  View on PubMed
  15. Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, Donovan RS, Shinjo F, Liu Y, Dembowy J, Taylor IW, Luga V, Przulj N, Robinson M, Suzuki H, Hayashizaki Y, Jurisica I, Wrana JL. High-throughput mapping of a dynamic signaling network in mammalian cells. Science. 2005 Mar 11; 307(5715):1621-5.  View on PubMed
  16. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science. 2005 Mar 11; 307(5715):1603-9.  View on PubMed
  17. Bose R, Hwang SW. Income and spending patterns among panhandlers. CMAJ. 2002 Sep 03; 167(5):477-9.  View on PubMed
  18. Bose R, Ahmad A, Dicks A, Novak M, Kayser K, McClelland R. Spectroscopic characterization by laser flash photolysis of electrophilic intermediates derived from 4-aminostilbenes. Stilbene "nitrenium" ions and quinone methide imines. Journal of the Chemical Society, Perkin Transactions 2. 1999; (8):1591 - 1600.  View on PubMed

Go to UCSF Profiles, powered by CTSI